Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cellectar Biosc (NQ: CLRB )

1.310 USD +0.040 (+3.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Cellectar Biosc

< Previous 1 2 3 4 5 6 7 Next >
Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
From GlobeNewswire News Releases
Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 10:00 am 
From GlobeNewswire News Releases
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
From GlobeNewswire News Releases
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
From GlobeNewswire News Releases
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico
New patent covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™ 
From GlobeNewswire News Releases
Cellectar to Participate at Upcoming Institutional Investor Conferences
From GlobeNewswire News Releases
Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates
Covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™ 
From GlobeNewswire News Releases
Cellectar to Participate at Upcoming Institutional Investor Conferences
From GlobeNewswire News Releases
AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and... 
From Business Wire News Releases
Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update
From GlobeNewswire News Releases
Cellectar to Present at BIO CEO & Investor Digital Conference
From GlobeNewswire News Releases
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia
Benefits include 10 years of market exclusivity in the European Union 
From GlobeNewswire News Releases
Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia
From GlobeNewswire News Releases
InvestorNewsBreaks – Cellectar Biosciences Inc. (NASDAQ: CLRB) Secures $45M in Underwritten Public Offering and Concurrent Private Placement
From InvestorBrandNetwork
Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
From GlobeNewswire News Releases
Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
From GlobeNewswire News Releases
Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement
From GlobeNewswire News Releases
Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
From GlobeNewswire News Releases
Cellectar Biosciences’ CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors
CLR 131 crosses blood brain barrier delivering drug directly to brain tumors 
From GlobeNewswire News Releases
Cellectar Biosciences to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients
40% overall response rate (ORR) with a total administered dose of 60 mCi or greater 
From GlobeNewswire News Releases
Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA
From GlobeNewswire News Releases
Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
From GlobeNewswire News Releases
Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting
Data highlight results from the Phase 1 study of CLR 131 in children and adolescents with relapsed/refractory malignancies 
From GlobeNewswire News Releases
Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting
Data highlight initial results of 100% overall response rate from ongoing Phase 2 trial in Relapsed or Refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM) 
From GlobeNewswire News Releases
Cellectar Appoints Dr. John Friend as Chief Medical Officer
From GlobeNewswire News Releases
Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles
Covers composition of matter and method of use into 2036 for proprietary PLE analogs in combination with various small molecule chemotherapeutics 
From GlobeNewswire News Releases
NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Secures $20.0M in Underwritten Public Offering
From InvestorBrandNetwork
Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering
From GlobeNewswire News Releases
Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]